We enable UK life science companies to develop their drug discovery projects. And through networks of expert labs and CROs our Virtual R&D team can access and provide:
> industrially rigorous advice in drug discovery
> clinical and commercial insight
> expertise in delivery and project management
If you are an SME with a drug discovery project, or a CRO with expertise to provide, attend this event and find out how we can help you.
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
Global Engage is pleased to announce the 2018 Precision Medicine & Biomarkers Leaders Summit USA taking place on May 7-8th in Boston, MA. The event is part of our highly successful Drug Discovery Series which includes conferences on Biologics, Medicinal Chemistry, NASH, Pharmaceutical R&D IT and the Human Microbiome amongst others. It is also the sister meeting of the European Precision Medicine Summit which has run successfully since 2013.
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
Global Engage is pleased to announce the 2018 Precision Medicine & Biomarkers Leaders Summit USA taking place on May 7-8th in Boston, MA. The event is part of our highly successful Drug Discovery Series which includes conferences on Biologics, Medicinal Chemistry, NASH, Pharmaceutical R&D IT and the Human Microbiome amongst others. It is also the sister meeting of the European Precision Medicine Summit which has run successfully since 2013.
Il processo di innovazione in atto: dalle strategie di brevettazione al fundr...Sardegna Ricerche
L'intervento di Rachele Berria (Global Vice President Primary Care Medical Unit Sanofi) in occasione dell'evento "Il valore della ricerca biomedica" che si è tenuto a Pula (CA) il 3 aprile 2019.
Accelerating the translation of medical research - 27 JuneInnovation Agency
Slides from the event focusing on translational research in Liverpool and North of England and why companies are establishing and growing operations in the region.
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
Tracks focus on R&D strategies, Biomarker development, Immuno-oncology, CDx development, AI and Big data analysis and approaches – Attending this Summit will provide you with the opportunity to mix and interact with experts working in all facets of Precision Medicine through the individual, panel and roundtable discussions on offer.
Clinical trial data wants to be free: Lessons from the ImmPort Immunology Dat...Barry Smith
Presentation to the Clinical and Research Ethics Seminar, Clinical and Translational Science Center, Buffalo, January 21, 2014
https://immport.niaid.nih.gov/
http://youtu.be/booqxkpvJMg
Medicines and vaccines have helped deliver improvements in patient health. History shows us the great advances we have made - today we continue to see the potential to eradicate disease and improve health outcomes when we invest in science and adopt and use new medicines.
Inhalation & Respiratory Drug Delivery SummitDiogo Ribeiro
The IRDD Summit will focus on the challenges of bringing respiratory products to market and innovative aerosol science, including modelling and toxicology. Presentations will also feature key case studies on the latest trends in inhalation devices, from inhaled insulin to gene therapy to overcome lung and pulmonary conditions, such as COPD, asthma and cystic fibrosis.
- Discover new methods for managing clinical next-gen data with insights from Pfizer, Boston Children’s Hospital and AstraZeneca
- Uncover and critique the latest technologies out there for you to use in clinical trials. Mayo Clinic, Merck and Harvard Medical School let you into their trade secrets
- Hear the genomics strategies that Roche, Millennium and Regeneron are using for discovery and validation of clinically actionable biomarkers
-Bristol-Myers Squibb, Takeda and Partners Healthcare the role that NGS can play when implementing an effective strategy in the lab to speed up CDx development
- Learn how to integrate molecular details into medical decision making, with fresh data from Washington University School of Medicine and Genzyme
An overview of our Technology Accelerator business model. We describe a hybrid model leveraging minimally-dilutive funding and experienced pharmaceutical management to “de-risk” and drive projects to IND. Our area of expertise is prodrugs and infectious diseases (www.tsrlinc.com).
How to Create a Big Data Culture in PharmaChris Waller
A talk presented at the Big Data and Analytics conference in Boston on January 28, 2014. Emphasis on data and information sharing cultures in companies.
We enable UK life science companies to develop their drug discovery projects. And through networks of expert labs and CROs our Virtual R&D team can access and provide:
> industrially rigorous advice in drug discovery
> clinical and commercial insight
> expertise in delivery and project management
If you are an SME with a drug discovery project, or a CRO with expertise to provide, attend this event and find out how we can help you.
Il processo di innovazione in atto: dalle strategie di brevettazione al fundr...Sardegna Ricerche
L'intervento di Rachele Berria (Global Vice President Primary Care Medical Unit Sanofi) in occasione dell'evento "Il valore della ricerca biomedica" che si è tenuto a Pula (CA) il 3 aprile 2019.
Accelerating the translation of medical research - 27 JuneInnovation Agency
Slides from the event focusing on translational research in Liverpool and North of England and why companies are establishing and growing operations in the region.
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
Tracks focus on R&D strategies, Biomarker development, Immuno-oncology, CDx development, AI and Big data analysis and approaches – Attending this Summit will provide you with the opportunity to mix and interact with experts working in all facets of Precision Medicine through the individual, panel and roundtable discussions on offer.
Clinical trial data wants to be free: Lessons from the ImmPort Immunology Dat...Barry Smith
Presentation to the Clinical and Research Ethics Seminar, Clinical and Translational Science Center, Buffalo, January 21, 2014
https://immport.niaid.nih.gov/
http://youtu.be/booqxkpvJMg
Medicines and vaccines have helped deliver improvements in patient health. History shows us the great advances we have made - today we continue to see the potential to eradicate disease and improve health outcomes when we invest in science and adopt and use new medicines.
Inhalation & Respiratory Drug Delivery SummitDiogo Ribeiro
The IRDD Summit will focus on the challenges of bringing respiratory products to market and innovative aerosol science, including modelling and toxicology. Presentations will also feature key case studies on the latest trends in inhalation devices, from inhaled insulin to gene therapy to overcome lung and pulmonary conditions, such as COPD, asthma and cystic fibrosis.
- Discover new methods for managing clinical next-gen data with insights from Pfizer, Boston Children’s Hospital and AstraZeneca
- Uncover and critique the latest technologies out there for you to use in clinical trials. Mayo Clinic, Merck and Harvard Medical School let you into their trade secrets
- Hear the genomics strategies that Roche, Millennium and Regeneron are using for discovery and validation of clinically actionable biomarkers
-Bristol-Myers Squibb, Takeda and Partners Healthcare the role that NGS can play when implementing an effective strategy in the lab to speed up CDx development
- Learn how to integrate molecular details into medical decision making, with fresh data from Washington University School of Medicine and Genzyme
An overview of our Technology Accelerator business model. We describe a hybrid model leveraging minimally-dilutive funding and experienced pharmaceutical management to “de-risk” and drive projects to IND. Our area of expertise is prodrugs and infectious diseases (www.tsrlinc.com).
How to Create a Big Data Culture in PharmaChris Waller
A talk presented at the Big Data and Analytics conference in Boston on January 28, 2014. Emphasis on data and information sharing cultures in companies.
We enable UK life science companies to develop their drug discovery projects. And through networks of expert labs and CROs our Virtual R&D team can access and provide:
> industrially rigorous advice in drug discovery
> clinical and commercial insight
> expertise in delivery and project management
If you are an SME with a drug discovery project, or a CRO with expertise to provide, attend this event and find out how we can help you.
Presented: 13th February 2019
Enabling successful project delivery through Virtual R&D
We enable UK life science companies to develop their drug discovery projects.
If you are an SME with a drug discovery project, or a CRO with expertise to provide, join this webinar and find out how we can help you.
Agenda:
- Introduction to Medicines Discovery Catapult
- What is Virtual R&D?
- The CRO Network
- The Expert Network
- The Benefits for SMEs and CROs / Experts
- Summary and time for questions
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the state of play for Complex Medicine and highlights the potential opportunity for the UK.
Prof Peter Simpson, Medicines Discovery Catapult
Customized Oncology Development Solutions: Clinical Trials Designed Around You®Covance
Oncology is one of the most research-intensive therapeutic areas, yet no two development programs are the same. No two trials are the same. Each one calls for a customized strategy and distinct trial management approach. Covance develops fit-for-purpose solutions Designed Around You® that enable more efficient clinical trials and focus on what is most valuable to your organization.
Why Precision Medicine and Personalized Healthcare and Why Now? Links to Canada’s Rare Disease Strategy The Future is Now
1) Marc LePage, Genome Canada
2) Michael Duong, Roche
3) Danica Stanimirovic, National Research Council
4) Daniel Gaudet, University of Montreal
5) Christine Dalgleish, Patient Perspective
6) Jamie Bruce, Khure Health
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
This expanding series attracts the leading authorities worldwide working in companion diagnostics, biomarkers, immuno-oncology, liquid biopsies, AI and other facets of precision medicine. It has been praised for its stimulating, interactive and engaging environment where it brings together a multi-disciplined community of researchers, leaders and innovators whose aim is to develop groundbreaking and impactful treatments for patients.
Find out about collaboration and partnership opportunities with the Wellcome Sanger Institute that aims to create exceptional healthcare opportunities for everyone from extraordinary science.
We can aid decision making from the pre-clinical to the clinical setting, supporting line of sight to the clinic, by identifying and translating crucial biomarker approaches into the real world.
In our final webinar of the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at overcoming the challenges of scaling up a complex medicine.
Graham Worrall and Emily Port, CPI
In our final webinar of the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the advantages of good formulation.
Claire Patterson, Seda Pharmaceutical Development Services
Our fifth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at physicochemical characterisation new and novel approaches to understand the pharmacokinetics of complex drugs.
Juliana Maynard (MDC)
Our fifth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at whether complex medicines raise different challenges from a safety perspective.
Richard Knight (Apconix)
Our fifth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at how you can determine efficacy in vivo.
Jenny Worthington (Axis Bio)
Our fourth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look Lipid Nanoparticles, and how there is so much more to them than being a little fat blob.
Yvonne Perrie (University of Strathclyde)
Our fourth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at alternative delivery for mRNA vaccines.
Helen McCarthy, pHion Therapeutics
Our fourth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at precision drug delivery with therapeutic microbubbles and the promise that they bring.
Louise Coletta, University of Leeds
Our third webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the interaction of colloidal gene delivery vehicles with model biomembranes.
Jayne Lawrence, The University of Manchester
Our third webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck gives an overview of the early assessment of Prototype Nanomedicine Nano Bio Interactions.
Zahra Rattray, University of Strathclyde
Our third webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the challenges of determining drug levels and pk profiles for complex drug modalities.
Robert Wheller, LGC
Our second webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at developing the assay cascade for complex medicines.
Tilly Bingham, Concept Life Sciences
Our second webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at CryoEM in characterisation and quality control of complex medicines
Dr Rebecca Thompson, Astbury Biostructure Laboratory
Our second webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at cellular internalisation and trafficking of complex medicines.
Dr Jamie Szczerkowski, Medicines Discovery Catapult
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the target landscape for Complex Medicine.
Dr Duygu Yilmaz, Medicines Discovery Catapult
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at Complex Medicine and articulates what the commercial opportunity could be.
David Cook, Blueberry Therapeutics
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Become a Medicines Discovery Catapult Partner - Glasgow
1. Accelerating innovative drug discovery
Connecting the UK drug discovery community
Transforming ideas into better medicines
for patients, faster
A NEW MODEL FOR
COLLABORATIVE R&D
2. National facility connecting the UK community
to accelerate innovative drug discovery
Medicines Discovery Catapult
WHO WHY HOW WHAT WHERE WORK WITH US
• Independent not-for-profit
• Part of the UK’s Catapult network
• Helping to deliver the UK’s Industrial Strategy
• Funded by Innovate UK, part of UK Research and Innovation,
reporting to the Department for Business, Energy & Industrial
Strategy
3. Pharma is facing unprecedented commercial pressure that force them to
reduce risk in their R&D pipelines1
In the UK:
SMEs account for more than 90% of our life sciences community2
But 42% of biotech SMEs have less than 5 employees3 and struggle to access:
WHO WHY HOW WHAT WHERE WORK WITH US
The industry is increasingly reliant on SMEs to innovate
Funding Expertise Technology
1. Deloitte (2017) A new future for R&D? Measuring the return from pharmaceutical innovation 2017.
2. HMG (2016) Strength and opportunity 2016: The landscape of the medical and biopharmaceutical sectors in the UK.
3. BIS (2015) Strength and opportunity 2015: The landscape of the medical technology and biopharmaceutical sectors in the UK.
SMEs are the agile risk-taking testers of new ideas, for innovation, discovery and
validation of new drugs and technologies
4. • Target specific industry-led challenges that limit today’s discovery process
• Industrialise, and drive the adoption of new scientific tools and modern techniques for discovering
medicines
• Deploy scarce expertise and know-how to connect a fragmented community and leverage current UK
infrastructure
• Support the UK life sciences industry, SMEs and innovators to deliver growth for the UK bio-economy
• Maintain the UK’s heritage position as a global leader in drug discovery
The enabling products and services that we diffuse into the sector will help UK SMEs fill their pipelines
with targeted medicines tested in patients, faster
WHO WHY HOW WHAT WHERE WORK WITH US
Our aims
Our vision
5. Providing hard-to-access
scientific capabilities
Gateway to UK resources
& expertise
By providing access to technologies and expertise not readily accessible we will support UK SMEs to
drive the development and widespread use of new approaches for the discovery of new medicines
WHO WHY HOW WHAT WHERE WORK WITH US
We are focussed on enabling UK drug discovery
6. We will not
• Compete with pharmaceutical or service companies
• Perform independent medicines discovery
• Replicate readily available UK infrastructure
We will prioritise and exemplify our efforts
• Outside of areas already covered
• In areas where UK science is perceived as ‘strong’
• In areas where SME needs are not met by others
• On development and promotion of cross-cutting discovery approaches
WHO WHY HOW WHAT WHERE WORK WITH US
We are focussed on enabling UK drug discovery
7. DISCOVERY SCIENCE
& TECHNOLOGY
INFORMATICS SAMPLES & DATA VIRTUAL R&D
DISCOVERY
SYNDICATES
Providing UK SMEs with access to technologies and expertise not readily accessible to them
WHO WHY HOW WHAT WHERE WORK WITH US
Our unique capabilities
Designed to address the needs of our UK drug discovery community and change the shape of R&D:
BETTER DATA FASTER
ACCESS TO RESOURCES & EXPERTISE
Underpinned by our skills & expertise in:
Funding Legal & IP Project management & delivery Business development
8. It is vital that SMEs developing new drug candidates access:
• Robust, well-characterised, sophisticated human models for pre-clinical testing
• Complex bioanalytical technologies to appropriately interrogate and advance
only the promising candidates faster
The creation of human models and bioanalytical technologies requires substantial
capital investment and specialist expertise
Discovery Science & Technology
Establishing patient-relevant testing models and
new technologies to advance drug discovery
Our strategy is built around four interconnected focus areas, supported
by innovative technology
BIOMARKERS FOR
PRECISION MEDICINE
COMPLEX CELL
MODELS
TARGET ENGAGEMENT
& VALIDATION
DRUG DELIVERY &
PRE-CLINICAL IMAGING
TECHNOLOGY
INNOVATION
WHO WHY HOW WHAT WHERE WORK WITH US
9. Who do we help?
Unique
Biology
Models
Advanced
Technologies
Drug Discovery
Expertise
Collaborative
Relationships
Real world evaluation
and application to
cutting edge science
Characterisation of lead molecules
in translatable models, using
cutting-edge technologies
Real world testing of models with
drug molecules and a suite of
advanced technologies
Drug Discovery
Companies
Technology
Companies
Biology
Companies
WHO WHY HOW WHAT WHERE WORK WITH US
10. BBB Spheroid
Pancreatic
Organoids on
chip
Vascularised
Cardiac
microtissue
Hepatocyte
Spheroids
Colorectal
Spheroids
Neurite
Dynamics
Kidney models
Disease relevant
iPSC
Cardiomyocytes
OOAC - Tissuse
OOAC – Second
platform
Scaffold
Supports
Drug Delivery
systems into
Cells
Strategic
Agreements
UK OOAC
network
Fibrosis
Neuro-
inflammation
Organ on a Chip (OOAC)
Connected Microphysiology
2D
3D spheroid
monolayer
DAPI
GFAP
NG2
DAPI
GFAP
CD31
50 um
Confocal microscopy images of a
blood brain barrier spheroid model
Complex cell models
WHO WHY HOW WHAT WHERE WORK WITH US
Replicating human physiology and pathophysiology
in vitro to enable better translation
Human Relevant
Predictive.
11. Biomarkers for precision medicine
WHO WHY HOW WHAT WHERE WORK WITH US
Transcriptomics
• RNA
• DNA
• Protein
Droplet digital PCR
Mass spec imaging
Mass Spectroscopy
• Lipidomics
• Metabolomics
• (peptides/proteins)
In vivo imaging
Biomarker Discovery
Biomarker Assay
Development
Biomarker Validation
Biomarker
prevalence
Early disease
linkage
studies
Human tissue
12. Profiling of complex biology and biomarkers
WHO WHY HOW WHAT WHERE WORK WITH US
Multiplexing quantification of up to 800 DNA, RNA and Protein molecules within a sample
• DNA
• RNA – mRNA, miRNA, fusion transcripts
• Protein expression
13. What canitdo?
Uniqueimagingsolutionsenablesquantificationof:
• Organ accumulation(PK,biodistribution)
• Targetexpressionorengagement(stratification)
• Biologicalactivity(PD,optimalbiologicaldose)
• Toxicitiesordrug-druginteractions(safety,drugcombinationstudy)
• Surrogacyforclinicalendpoint(efficacy)
What canwedo?
Imaging Expertiseinmulti-parametricimagingmodalities:
• PositronEmissionTomography(PET)
• ComputedTomography(CT)
• HighFrequencyUltrasound(HFUS)
• Gamma countingex-vivoanalysis
• Nearinfraredopticalimaging
Targeted Drug Delivery
WHO WHY HOW WHAT WHERE WORK WITH US
Using Imaging technologies to visualise biological
functions to accelerate disease understanding and drug
development
14. Target engagement & validation
WHO WHY HOW WHAT WHERE WORK WITH US
Strategy
• Does my compound reach its desired site of action?
• Does my compound engage with its molecular target in cells?
• What are the downstream consequences of compound/target binding?
In translatable
human cell models
At single-cell
resolution
15. Target engagement & validation
WHO WHY HOW WHAT WHERE WORK WITH US
Compound-Target Interaction with
Purified Protein
Direct Measurement of
Compound-Target
Interaction in Cells
Target Conformational
Change in Cells
Proximal pathway events
following target engagement
Distal pathway events following
target engagement
Super-Resolution Microscopy
Fluorescence Polarisation & FCS
BRET/FRET
Protein Stability
Dimerisation
Localisation
Cellular Mass-Spectrometry +/- Target
Knockdown
Cellular Mass-Spectrometry +/- Target Knockdown
Transcriptomics +/- Target Knockdown
Microscopy
build from
4Q’18
Target
Engagement
Target
Validation
Establishing
assay methods to
interrogate
TE/TV at all
levels
Solid-state NMR
Mass-Spectrometry
16. Mass spec imaging capabilities
WHO WHY HOW WHAT WHERE WORK WITH US
DESI-MSimaging;CD1micetumourxenografts
• Smallmoleculeexpressiondifferences
• Noveltargeteddeliverymethod
Instrumentation
Q-TOF
TQ-XS
DESI
Image visualisation
software
Application /
exploitation
17. WHO WHY HOW WHAT WHERE WORK WITH US
Drug discovery generates a huge quantity of complex biological, chemical,
clinical and safety information
To make the best decisions on which assets to further optimise or progress, and to
create the best data assets, secure sharing and associated data analytics are critical
Informatics
Using data science to discover new diagnostics,
biomarkers and drugs
Using our informatics skills, extensive proprietary databases and algorithms
we can help validate and drive adoption of new data-driven approaches
NOVEL DRUG COMBINATIONS
In silico TARGET VALIDATION
USING REAL WORLD DATA
DRUG REPURPOSING
EFFICACY AND SAFETY
ANALYSIS
UNDERSTANDING
CHEMICAL SPACE
DRUGGABILITY
We have deep expertise in scientific data analysis, information extraction,
natural language processing and machine learning
18. Core themes
WHO WHY HOW WHAT WHERE WORK WITH US
Collaborative Intelligence
• Mapping the UKs life science capability
Interoperable Data
• Inter-organization ELN data transfer
• Connected Data
• ‘Data on demand’ – better coverage of known facts
• Drug repositioning & reformulation – maximise asset use
• Synergistic drug combinations – chimeras, blends, cocktails
• Drug resistance – AMR, cancer, antivirals
• Leads for new target classes – not PPIs – channels, transporters, viruses…
Target Prioritization
• Variant Effect Prediction – ‘multiscale’ approach
• Target Validation - druggability & efficacy
e.g., small molecule protein kinase inhibitor
benchmark set. N=746
IT
Academic
Large
Pharma
Therapeutic
SME
CRO
Single Drug Multiple Drugs
SingleTargetMultipleTargets
Combination
Therapy
Classic Drug
Discovery,
Ehrlich’s ‘Magic
Bullet’
Drug Blending
Designed/Serendipitous
Polypharmacology
Drug
Target
Biochemic
al assay
Cell-
based
screen
Function
al assay
Animal
disease
model
Human
clinical
trial
ChEMBL MDC Clinicaltrials.gov
19. IT
Academic
Large Pharma
Therapeutic
SME
CRO SME
Mapping capability
WHO WHY HOW WHAT WHERE WORK WITH US
Challenges for the community
• Finding the best collaborators
• ‘Entry-level’ e.g., one-off experiments, running a few
compounds through an assay…
• ‘Discoverability’ and ‘commercial inertia’ are big factors
UK inventory and map of drug discovery capability
• Companies House, Charities Commission, Patents,
Published Papers, Grant Applications, UK Universities,
Theses, Professional Societies, Consultant Networks…..
• Text-mining/Semantic Web, technical focus on
name/organization ‘grounding’
20. WHO WHY HOW WHAT WHERE WORK WITH US
The UK has millions of samples and billions of data points collected from
patients who have agreed their samples and data can be used for
research
However, small UK medical research companies struggle to access them
“Over 90% of SMEs said that access to high quality clinical samples was important,
however 80% found accessing samples unexpectedly difficult.”1
Samples & Data
Brokering easier access to consented patient
data and samples
We are working with key organisations supporting access to
consented tissues & data:
DIRECTORIES
RESEARCH
SERVICES
PROCUREMENT SERVICES
21. Access to samples is required by the sector
WHO WHY HOW WHAT WHERE WORK WITH US
Objectives
• Support UK SMEs in the supply of consented human tissue
• Set up collaborations with UK biobanks
• Provide access to expertise – Tissue Solutions
• A world leading provider of quality human tissue samples
• Benefit from connections and expertise
• Provide SMEs with required samples in a timely, cost
effective manner
• Provide vital cost recovery to biobanks to ensure that high
quality collections can be maintained
-100% 0% 100%
Access to biosamples for commercial
development is hugely important
It is easy to access high quality NHS biosamples
for commercial research
Access to the right health data such as registries
and activity is hugely important for innovative
companies
It is easy to access the right health data such as
registries and activity
The UK has a clear framework and process for the
commercialisation of NHS health data
Please could you indicate how much you agree / disagree with these
statements:
Neither agree nor disagree Somewhat agree Strongly agree
Somewhat disagree Strongly disagree
22. The ecosystem surrounding medicines discovery is highly
fragmented and complex
42% of biotech SMEs have less than 5 employees1 and are unable to efficiently
access the UK’s rich resources in translational research
Virtual R&D
Leveraging the UK’s renowned leadership
in drug discovery – a modern approach to R&D
Our VR&D platform uses a unique national network of up-to-date industry-
skilled consultants and service providers to deliver three essential elements
VR&D will deliver value to finance, biotech, academia and charities
1. BIS (2015) Strength and opportunity 2015: The landscape of the medical technology and
biopharmaceutical sectors in the UK.
WHO WHY HOW WHAT WHERE WORK WITH US
‘Pop-up’ Advisory teams
Virtual programme
management
UK capability map
23. Drug discovery is complex, costly and resource intensive
WHO WHY HOW WHAT WHERE WORK WITH US
Complex web of service providers, enablers and funders is challenging to navigate
Successful projects require:
• Enablers; CROs, specialist academic institutes, etc
• Knowledge; Decision making advice and expertise in drug discovery
• Delivery; Experienced drug discovery project management and due diligence
TI/TV
Hit
finding
Med.
Chem.
Pharmacology
Biomarkers
IND
enabling
Cell
models
Assay
generation
Comp.
Chem.
Library
design
Synth.
Chem.
Analyt.
Chem.
Process
Chem.
Formulation
In vivo
models
In vivo
efficacy
ADME
PK
PD
Dose to
man
Safety
GLP
tox
Idea
Drugcandidate
24. The UK: strength in basic science and a vibrant biopharma sector > 650 businesses
• BUT 11x less follow-on investment than US hubs
• 42% businesses <5 employees and the sector is fragmented and hard-to-navigate
9th Annual Report Office for Life Sciences, May 2018
Understand future market
Identify untapped opportunities
Best practice concept testing
Navigating the NHS to set up high
quality single centre trials
Advice on appropriate
models of efficacy and
safety
Biomarker and/or personalised
medicine strategy
Project
management
Advice on appropriate research
options – quality and price
Target ID &
validation
Lead
generation
Optimisation
Candidate
selection
First-in-
human trials
Exploratory
clinical trials
Proof of
concept
Launch
Secure
capital
WHO WHY HOW WHAT WHERE WORK WITH US
Why companies may want to seek expert support
25. An academy of excellence to guide SME drug discovery
WHO WHY HOW WHAT WHERE WORK WITH US
Benefits and desired outcomes
• Leveraging existing expertise for
the benefit of UK SMEs
irrespective of location
• Critical advice and due diligence
for drug discovery projects
• Identifying new opportunities for
interaction and collaboration
• Creating a connected eco-system
of expertiseCentres of excellence
existing networks and
consultants:
Connecting expertise
in drug discovery
and clinical science.
Timely, flexible support
for business critical decisions
+
UK strength in
drug discovery
27. • Management of the virtual project team
• Alignment of a functional network of CROs, specialist
academic providers in addition to MDC capabilities to
deliver the project
• Provision of expertise to guide the project through
agreed milestones with associated Go/No Go
decisions for progression
WHO WHY HOW WHAT WHERE WORK WITH US
Medicines Discovery Catapult Virtual R&D Project Delivery
28. Clinical Development
Clinical
End to end services
Disease agnostic
Disease
specific
Niche
WHO WHY HOW WHAT WHERE WORK WITH US
Virtual R&D Project Delivery A Functional Network of CROs
29. • Existing relationships with CROs and knowledge of the
service/ expertise offered
• Medicines Discovery Catapult Informaticians identify
specialist & niche provision
• Development of expertise by Medicines Discovery
Catapult internal capability
• Management of relationships between CROs
• Facilitate administrative and contractual process
WHO WHY HOW WHAT WHERE WORK WITH US
Access to a Functional Network of CROs: The Advantages
31. What expertise or
capability is offered by
your CRO?
What expertise is needed
in our CRO Network?
Medicines Discovery
Catapult
Business Development and
Communications
Access to new and
larger markets
1. Qualitative due diligence
2. What is the Business Model?
• Revenue?
• Contractual Structure?
WHO WHY HOW WHAT WHERE WORK WITH US
Joining the Network of CROs
32. Who can we help?
WHO WHY HOW WHAT WHERE WORK WITH US
Real world evaluation and due diligence
Execution of project plans
New business for service providers
Opportunities for collaborative R&D
Start Ups,
Spin Outs
TTOs,
VCs
Drug Discovery
SMEs and CROs
Project management and drug discovery expertise
Access to drug discovery and disease area expertise
Relationships with CRO and specialist academic service providers
33. WHO WHY HOW WHAT WHERE WORK WITH US
As only patients know what it’s like to live with a disease, it’s crucial they
play a more central role in medical research
Talking to patients is often a better way to find out what medical products need to
developed, yet it doesn’t always happen
Discovery Syndicates
Spearheading patient involvement in early
drug discovery – a collective approach to R&D
Discovery Syndicates are a new, shared-resource model for disease focussed
consortia
Anchored by the leading medical research charity and centred
around patient needs
De-risk new promising assets
and drive commercialisation
Develop a patient centric
cohesive research agenda
Identify key barriers to
translation for a disease
Accelerate translation of
research to the clinic
Create new and more efficient
funding and investment models
34. WHO WHY HOW WHAT WHERE WORK WITH US
National facility and laboratory
Our office and laboratories are based at Alderley Park in Cheshire
Providing UK SMEs with access to the UK’s second largest life sciences cluster and unrivalled opportunities
35. md.catapult.org.uk
@meddisccat
info@md.catapult.org.uk
01625 238734
Visit our website for our latest partnerships and
funding opportunities.
Get in touch for more information, expert guidance,
strategic consultancy and access to our technology.
Or to discuss a potential project or service.
WHO WHY HOW WHAT WHERE WORK WITH US
Get in touch now
Editor's Notes
Key technology to allow more data from less tissue
MDC currently validating 3D approach for clinical application (protein addition).
to compare to validated sample set with IHC data generated to compare to – quantitative readout.
Nanostring developing tech to build incorporating the spacial profiling.
Initially interested on using this for oncology application (PoC) but our interests lie on applying this to other disease areas
Tie this into tissue imaging capability